Young cancer survivors are at increased risk for developing HPV-related malignancies, with female and male survivors at 1.4- to 2.5-fold excess risk, respectively, compared with the general population ...

Vaccine R&D has been revitalized recently in part owing to major commercial successes and increased incentives for products that address neglected diseases. Our interviewees this month describe ...

This collection aims to gather the state of the art of therapeutic HPV vaccine research – from novel vaccine design concepts, to preclinical models, to results of clinical trials. This ...

Gardasil is a vaccine, licensed for use in June 2006, by the FDA. It targets four strains of human papillomavirus (HPV ... How long is Gardasil effective? Research suggests the vaccine lasts ...

The abstracts will showcase research ... a dedicated poster session. PDS Biotech is committed to innovating immunotherapy approaches for cancer treatment, specifically targeting HPV-associated ...

The findings from Fred Hutch Cancer Center suggest next step of exploring whether one dose of the vaccine is enough.